A.Shaller/Rotterdam Image Bank

PRRT (Peptide Receptor Radionuclide Therapy) is given to patients with neuroendocrine tumors (NETs). The main mechanism of the treatment via the receptors on these tumors.


The vast majority of neuroendocrine tumors has receptors that bind somatostatin. NETs can be made visible by means of a scan by coupling a lightly radioactive compound to the protein or hormone somatostatin and then injecting the radiopeptide it in patients.


The first form of PRRT was developed at the Nuclear Medicine Department of the Erasmus MC, and was used for the first time in humans in 1992.


This method of imaging has now become the global standard and is used to detect NETs and divide them into stages. This scan is known as Somatostatin Receptor Scan (SRS) or OctreoScan.


Soon after this discovery the idea developed that it could be possible to use this method for therapy as well. The first PRRT treatment with Indium octreotate (a precursor of lutetium octreotate) was given in Rotterdam in 1992.


PRRT Treatment Center Rotterdam is located at the Nuclear Medicine Department at the Erasmus MC. The name PRRT Treatment Center Rotterdam was given to the center in 2014 with the aim to make this specialist treatment center better known.

Treatment and Results

The current form of PRRT treatment with lutetium octreotate was also first applied in Rotterdam. Ever since, more than 5000 therapies have been given to more than 1300 patients, with positive results. Around 40% of the treated patients came from abroad.


The staff of the PRRT Treatment Center Rotterdam remains committed to increasing the quality of life of patients with NET. Thanks to our team, patients rate the overall treatment with an 8,9.

Center of Excellence Certificate

The Erasmus MC was one of the first six hospitals in Europe to receive the certificate “ENETS Center of Excellence” in 2009. Read more about ENETS Center of Excellence.


If you have questions about PRRT or NET, please contact us.